000076036 001__ 76036
000076036 005__ 20201009175922.0
000076036 0247_ $$2doi$$a10.1016/j.ijpharm.2017.04.022
000076036 0248_ $$2sideral$$a98969
000076036 037__ $$aART-2017-98969
000076036 041__ $$aeng
000076036 100__ $$aAragon, J.$$uUniversidad de Zaragoza
000076036 245__ $$aLaser-treated electrospun fibers loaded with nano-hydroxyapatite for bone tissue engineering
000076036 260__ $$c2017
000076036 5060_ $$aAccess copy available to the general public$$fUnrestricted
000076036 5203_ $$aCore-shell polycaprolactone/polycaprolactone (PCL/PCL) and polycaprolactone/polyvinyl acetate (PCL/PVAc) electrospun fibers loaded with synthesized nanohydroxyapatite (HAn) were lased treated to create microporosity. The prepared materials were characterized by XRD, FTIR, TEM and SEM. Uniform and randomly oriented beadless fibrous structures were obtained in all cases. Fibers diameters were in the 150–300 nm range. Needle-like HAn nanoparticles with mean diameters of 20 nm and length of approximately 150 nm were mostly encase inside the fibers. Laser treated materials present micropores with diameters in the range 70–120 µm for PCL-HAn/PCL fibers and in the 50–90 µm range for PCL-HAn/PVAC material. Only samples containing HAn presented bioactivity after incubation during 30 days in simulated body fluid. All scaffolds presented high viability, very low mortality, and human osteoblast proliferation. Biocompatibility was increased by laser treatment due to the surface and porosity modification.
000076036 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/CTQ2014-52384-R
000076036 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000076036 590__ $$a3.862$$b2017
000076036 591__ $$aPHARMACOLOGY & PHARMACY$$b46 / 261 = 0.176$$c2017$$dQ1$$eT1
000076036 592__ $$a1.172$$b2017
000076036 593__ $$aPharmaceutical Science$$c2017$$dQ1
000076036 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000076036 700__ $$0(orcid)0000-0003-3363-2912$$aNavascues, N.
000076036 700__ $$0(orcid)0000-0003-2293-363X$$aMendoza, G.
000076036 700__ $$0(orcid)0000-0002-2966-9088$$aIrusta, S.$$uUniversidad de Zaragoza
000076036 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000076036 773__ $$g525, 1 (2017), 112-122$$pInt. j. pharm.$$tInternational Journal of Pharmaceutics$$x0378-5173
000076036 8564_ $$s1178370$$uhttps://zaguan.unizar.es/record/76036/files/texto_completo.pdf$$yPostprint
000076036 8564_ $$s44300$$uhttps://zaguan.unizar.es/record/76036/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000076036 909CO $$ooai:zaguan.unizar.es:76036$$particulos$$pdriver
000076036 951__ $$a2020-10-09-17:46:36
000076036 980__ $$aARTICLE